Fundraising Fox
中裕新藥
Founded 2007 · 49 employees on LinkedIn · 1 known investors
Find your way into 中裕新藥
Sign up to see every warm intro you have to 中裕新藥
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 中裕新藥 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.
Founders & leadership
JC
Jimmy ChangCEO
Investors · 1
Frequently asked questions
- What does 中裕新藥 do?
- TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.
- Who are 中裕新藥's investors?
- 中裕新藥's investors include YFY Biotech Management Company.